Chemotherapy-induced Peripheral Neuropathy Clinical Trial
— QLIPP-CIPNOfficial title:
Patient-centered Development and Effectiveness of Online Acceptance and Commitment Therapy for Pain Interference in Cancer Survivors With Persistent Painful Chemotherapy-induced Neuropathy
Rationale: An average of 30% of adult cancer survivors suffers from chemotherapy-induced peripheral neuropathy (CIPN) ≥ 6 months after completion of chemotherapy, and their quality of life (QoL) is strongly affected due to these symptoms. Treatment options are limited. Objective: The goal of this study is to examine the effectiveness of an online psychological intervention based on Acceptance and Commitment Therapy (ACT) in a Randomized Controlled Trial (RCT) and compared to a treatment-as-usual control condition (TAU). We aim to improve pain interference in cancer survivors with chronic painful CIPN (present for at least 3 months) in the curative disease phase who were treated with chemotherapy treatment at least 6 months ago (irrespective of disease site). Study design: It concerns a test of effectiveness of the ACT intervention in an RCT on quality of life. In total, 146 participants will be randomly allocated to one of two groups: the online ACT intervention with therapist email guidance or a control condition that receives treatment-as-usual. Patients in the control condition can follow the online ACT intervention directly after the 3 month-follow up measurement. Self-reported questionnaires will be conducted at baseline, after the intervention, and at 3- and 6-month follow-up. Additionally, interviews will be executed with a subgroup of interested patients afterwards, to explore intervention effects more in-depth. Participants will be sampled via various patient organizations, oncologists, and advertisements distributed via the PROFILES-registry that contains ongoing research projects on CIPN. Data will be collected online via the PROFILES-registry. Study population: The population consists of adult cancer survivors in the curative disease phase suffering from painful CIPN for at least 3 months and who received chemotherapy treatment 6 or more months ago. Intervention: An online ACT intervention was developed in the first phase of the QLIPP-CIPN study. In this study phase insights into daily limitations and quality of life of the patient population were gained, which served as the basis of the patient-centered development of the online ACT intervention following the CeHRes roadmap for participatory eHealth design. The intervention includes an 8-week self-management course containing 6 modules regarding psycho-education and ACT- processes. By means of text and exercises people learn to carry out value-oriented goals in daily life with pain. To do this, they learn new ways of coping with pain, including reducing pain avoidance and increasing pain acceptance. Additionally, participants will receive email guidance. Main study parameters/endpoint: Pain interference in daily life using subscale Interference of the Multidimensional Pain Inventory (MPI). This scale focuses on a psychosocial aspect of chronic pain, specifically the interference with functioning in, for example, work, homework chores, recreational and social activities due to pain. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participation is not expected to have any risks. Participants can quit the study at any moment and will not be excluded based on medication use or other current treatment for CIPN. If participants regress during the intervention and need new chemotherapy treatment, they can choose if they will continue or not. Participants do need to invest time to follow the intervention, which takes around 2 hours per week. Furthermore, it might be confronting to work on pain acceptance for participants. Benefits of participation are foremost a possible improvement in pain interference and reductions in pain and CIPN symptoms.
Status | Recruiting |
Enrollment | 146 |
Est. completion date | December 1, 2023 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: 1. age of 18 years or older, 2. identified by a clinician or self as having painful sensations (i.e., aching, burning, ''pins-and-needles'', shock-like, painful tingling, numbness, cramps) bilaterally in the feet/legs and/or hands/arms for at least 3 months. Furthermore, 3. score a 3 or higher on an 11-point pain intensity scale (Numeric Rating Scale), 4. the pain was not present prior to receiving chemotherapy, 5. chemotherapy ended at least 6 months ago. Exclusion criteria: 1. enrollment in psychological treatment related to cancer, pain, or psychiatry upon entry, 2. new chemotherapy scheduled during study participation, 3. no access to the Internet/no email address, 4. not enough time to follow the intervention (2 hours per week), 5. problems with the Dutch language. |
Country | Name | City | State |
---|---|---|---|
Netherlands | Tilburg University | Tilburg | Noord-Brabant |
Lead Sponsor | Collaborator |
---|---|
Daniëlle van de Graaf | Comprehensive Cancer Centre The Netherlands, Dutch Cancer Society |
Netherlands,
Hayes, S. C., Strosahl, K., and Wilson, K. G. (2012) Acceptance & Commitment Therapy: The process and practice of mindful change 2nd. Guilford Press.
van de Poll-Franse LV, Horevoorts N, Schoormans D, Beijer S, Ezendam NPM, Husson O, Oerlemans S, Schagen SB, Hageman GJ, Van Deun K, van den Hurk C, van Eenbergen M, Mols F; Profiles Registry Group. Measuring Clinical, Biological, and Behavioral Variables to Elucidate Trajectories of Patient (Reported) Outcomes: The PROFILES Registry. J Natl Cancer Inst. 2022 Feb 24. pii: djac047. doi: 10.1093/jnci/djac047. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Interviews | Qualitative data on intervention effects and satisfaction will be collected by means of interviews with some participants after completion of the intervention | T3 (2 months) | |
Other | Interviews | Qualitative data on intervention effects and satisfaction will be collected by means of interviews with some participants after completion of the intervention | T5 (8 months) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T0b (0 months) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T1 (3 weeks) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T2 (6 weeks) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T3 (2 months) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T4 (5 months) | |
Primary | Pain interference | Multidimensional Pain Inventory - Dutch Language Version (MPI-DLV). Subscale Interference. Minimum = 0, maximum = 60. Higher score means worse outcome. | T5 (8 months) | |
Secondary | Cancer related quality of life | European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30). Minimum = 30, maximum = 126. Higher score means better outcome. | T0b (0 months) | |
Secondary | Cancer related quality of life | European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30). Minimum = 30, maximum = 126. Higher score means better outcome. | T3 (2 months) | |
Secondary | Cancer related quality of life | European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30). Minimum = 30, maximum = 126. Higher score means better outcome. | T4 (5 months) | |
Secondary | Cancer related quality of life | European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core-30 item (EORTC QLQ-C30). Minimum = 30, maximum = 126. Higher score means better outcome. | T5 (8 months) | |
Secondary | CIPN symptom severity | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Minimum = 0, maximum = 60. Higher score means worse outcome. | T0a (0 months) | |
Secondary | CIPN symptom severity | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Minimum = 0, maximum = 60. Higher score means worse outcome. | T3 (2 months), | |
Secondary | CIPN symptom severity | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Minimum = 0, maximum = 60. Higher score means worse outcome. | T4 (5 months) | |
Secondary | CIPN symptom severity | European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Minimum = 0, maximum = 60. Higher score means worse outcome. | T5 (8 months) | |
Secondary | Pain intensity | Numeric Rating Scale (NRS-11). Minimum = 0, maximum = 20. Higher score means worse outcome. | T0a (0 months) | |
Secondary | Pain intensity | Numeric Rating Scale (NRS-11). Minimum = 0, maximum = 20. Higher score means worse outcome. | T3 (2 months) | |
Secondary | Pain intensity | Numeric Rating Scale (NRS-11). Minimum = 0, maximum = 20. Higher score means worse outcome. | T4 (5 months) | |
Secondary | Pain intensity | Numeric Rating Scale (NRS-11). Minimum = 0, maximum = 20. Higher score means worse outcome. | T5 (8 months) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T0b (0 months) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T1 (3 weeks) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T2 (6 weeks) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T3 (2 months) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T4 (5 months) | |
Secondary | Pain catastrophizing | Pain Catastrophizing Scale (PCS). Minimum = 0, maximum = 65. Higher score means worse outcome. | T5 (8 months) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T0b (0 months) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T1 (3 weeks) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T2 (6 weeks) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T3 (2 months) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T4 (5 months) | |
Secondary | Psychological distress | Hospital Anxiety and Depression Scale (HADS). Minimum = 0, maximum = 56. Higher score means worse outcome. | T5 (8 months) | |
Secondary | Psychological flexibility | Psychological Inflexibility in Pain Scale (PIPS). Minimum = 0, maximum = 84. Higher score means worse outcome (higher score means more inflexibility). | T0a (0 months) | |
Secondary | Psychological flexibility | Psychological Inflexibility in Pain Scale (PIPS). Minimum = 0, maximum = 84. Higher score means worse outcome (higher score means more inflexibility). | T1 (3 weeks) | |
Secondary | Psychological flexibility | Psychological Inflexibility in Pain Scale (PIPS). Minimum = 0, maximum = 84. Higher score means worse outcome (higher score means more inflexibility). | T2 (6 weeks) | |
Secondary | Psychological flexibility | Psychological Inflexibility in Pain Scale (PIPS). Minimum = 0, maximum = 84. Higher score means worse outcome (higher score means more inflexibility). | T3 (2 months) | |
Secondary | Psychological flexibility | Psychological Inflexibility in Pain Scale (PIPS). Minimum = 0, maximum = 84. Higher score means worse outcome (higher score means more inflexibility). | T4 (5 months) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T0b (0 months) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T1 (3 weeks) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T2 (6 weeks) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T3 (2 months) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T4 (5 months) | |
Secondary | Mindfulness | Freiburg Mindfulness Inventory (FMI). Minimum = 0, maximum = 56. Higher score means better outcome. | T5 (8 months) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T0b (0 months) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T1 (3 weeks) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T2 (6 weeks) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T3 (2 months) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T4 (5 months) | |
Secondary | Values-based living | Engaged Living Scale (ELS). Minimum = 0, maximum = 80. Higher score means better outcome. | T5 (8 months) | |
Secondary | Intervention evaluation (Based on: Trompetter et al. (2015)). | Questions:
During the past few weeks, how many hours did you spend on average per week working on the online course? On average, how many days per week did you do mindfulness exercises during the past few weeks? On the days you practiced mindfulness: On average, how many minutes did you spend practicing? How do you rate the quality of the online training you received? Did you receive the kind of help you were hoping to receive? To what extent did the online training meet your needs? Suppose one of your acquaintances needed the same help, would you recommend the online training? How satisfied are you with the amount of help you received? Did the online training help you cope better with your problems? Overall, how satisfied are you with the online training you received? Would you do the online training again if you needed to? What grade would you give the online training? |
T3 (2 months) (ACT) | |
Secondary | Intervention evaluation (Based on: Trompetter et al. (2015)). | Questions:
During the past few weeks, how many hours did you spend on average per week working on the online course? On average, how many days per week did you do mindfulness exercises during the past few weeks? On the days you practiced mindfulness: On average, how many minutes did you spend practicing? How do you rate the quality of the online training you received? Did you receive the kind of help you were hoping to receive? To what extent did the online training meet your needs? Suppose one of your acquaintances needed the same help, would you recommend the online training? How satisfied are you with the amount of help you received? Did the online training help you cope better with your problems? Overall, how satisfied are you with the online training you received? Would you do the online training again if you needed to? What grade would you give the online training? |
T5 (8 months) (WLC) | |
Secondary | Adherence | Adherence will be based on technical data obtained from Karify's online environment. The following information will be used for this purpose.
Sent messages: the moment when a message is sent to the supervisor. Given feedback: the moment when feedback is given on a specific assignment. Significant moment: first_viewed: the moment when an assignment is viewed for the first time. Significant moment: finished: the moment when an assignment is handed in for the first time. This will possibly be combined with the number of hours spent on intervention (self-reported), as described under 'intervention evaluation'. |
T5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
Completed |
NCT03272919 -
Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
Not yet recruiting |
NCT06430814 -
Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
|
||
Not yet recruiting |
NCT05840562 -
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
|
Phase 3 | |
Completed |
NCT02553863 -
The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04786977 -
Physiologic Measure of VIPN
|
||
Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
Completed |
NCT03687970 -
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
|
N/A | |
Terminated |
NCT04770402 -
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
|
N/A | |
Completed |
NCT03254394 -
Lidocaine for Oxaliplatin-induced Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT04367480 -
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
Recruiting |
NCT04237194 -
A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
|
||
Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
Terminated |
NCT03782402 -
Cannabinoids for Taxane Induced Peripheral Neuropathy
|
Phase 2 | |
Not yet recruiting |
NCT06389721 -
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
|
||
Recruiting |
NCT05121558 -
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
|
Phase 3 | |
Withdrawn |
NCT04492436 -
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
|
Phase 2 | |
Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
Completed |
NCT04262778 -
Diagnostic of Chemotherapy Induced Neuropathy in Children
|
||
Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A |